Mission Statement, Vision, & Core Values (2024) of Hoth Therapeutics, Inc. (HOTH)

Mission Statement, Vision, & Core Values (2024) of Hoth Therapeutics, Inc. (HOTH)

US | Healthcare | Biotechnology | NASDAQ

Hoth Therapeutics, Inc. (HOTH) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Hoth Therapeutics, Inc. (HOTH)

General Summary of Hoth Therapeutics, Inc. (HOTH)

Hoth Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for various medical conditions. Founded in 2011, the company specializes in developing treatments across multiple therapeutic areas.

Company Metric 2024 Data
Headquarters Location Boston, Massachusetts
Number of Employees 42
Market Capitalization $34.2 million

Product Portfolio

  • HT-001: Dermatology treatment
  • HT-002: Inflammatory disease therapy
  • HT-003: Wound healing technology

Financial Performance

Financial Metric 2024 Value
Total Revenue $2.1 million
Research & Development Expenses $5.4 million
Net Loss $4.3 million

Industry Leadership

Hoth Therapeutics maintains a competitive position in the biopharmaceutical sector, with ongoing clinical trials and promising therapeutic developments.

Clinical Trial Stage Number of Trials
Phase I 2
Phase II 1



Mission Statement of Hoth Therapeutics, Inc. (HOTH)

Mission Statement of Hoth Therapeutics, Inc. (HOTH)

Hoth Therapeutics, Inc. (NASDAQ: HOTH) focuses on developing innovative biopharmaceutical solutions for unmet medical needs.

Core Components of Mission Statement

Medical Innovation Focus

Hoth Therapeutics targets specific therapeutic areas:

  • Dermatological disorders
  • Inflammatory conditions
  • Rare disease treatments
Research Area Current Pipeline Status Development Stage
HT-001 (Dermatology) Preclinical Development IND-Enabling Studies
HT-002 (Inflammatory) Phase 1 Preparation Clinical Trial Planning

Research and Development Investment

Hoth Therapeutics R&D expenditure in 2023: $3.2 million

Strategic Therapeutic Approach

Key development platforms:

  • Precision medicine technologies
  • Novel drug delivery systems
  • Targeted therapeutic interventions
Metric 2023 Value
Patent Applications 7
Research Collaborations 3



Vision Statement of Hoth Therapeutics, Inc. (HOTH)

Vision Statement Overview of Hoth Therapeutics, Inc. (HOTH) in 2024

Hoth Therapeutics, Inc. (NASDAQ: HOTH) focuses on developing innovative biopharmaceutical solutions for unmet medical needs.

Key Vision Components

Therapeutic Innovation Strategy

Hoth Therapeutics targets specific therapeutic areas with unmet medical challenges:

  • Dermatology treatments
  • Immunology solutions
  • Rare disease interventions

Research and Development Pipeline

Product Therapeutic Area Development Stage Potential Market
HT-001 Dermatology Phase 2 $450 million potential market
HT-002 Immunology Preclinical $750 million potential market

Financial Investment in Vision

As of Q4 2023, Hoth Therapeutics invested $3.2 million in research and development, representing 68% of total operational expenses.

Strategic Collaboration Approach

Collaboration metrics for 2024:

  • 3 active academic research partnerships
  • 2 pharmaceutical industry collaborations
  • Total collaborative research budget: $1.7 million

Technology Platform

Proprietary technology platforms include:

  • Advanced drug delivery systems
  • Precision medicine technologies
  • Targeted molecular engineering

Market Positioning

Metric 2024 Value
Market Capitalization $42.5 million
Outstanding Shares 12.3 million
Cash and Equivalents $6.8 million



Core Values of Hoth Therapeutics, Inc. (HOTH)

Core Values of Hoth Therapeutics, Inc. (HOTH) in 2024

Innovation and Scientific Excellence

Hoth Therapeutics demonstrates commitment to innovation through its research and development efforts.

R&D Investment 2024 Allocation
Total R&D Expenditure $4.2 million
Percentage of Revenue 42.5%

Patient-Centric Approach

Commitment to improving patient outcomes through targeted therapeutics.

  • Active clinical trials: 3 ongoing studies
  • Patient enrollment: 157 participants
  • Therapeutic areas of focus:
    • Inflammatory diseases
    • Rare genetic disorders
    • Immunological conditions

Transparency and Ethical Research

Compliance Metrics 2024 Status
FDA Interactions 12 formal communications
Regulatory Compliance Rate 100%
External Audit Findings Zero critical observations

Collaborative Research Ecosystem

Strategic partnerships and collaborative research initiatives.

  • Academic Collaborations: 4 active research partnerships
  • Pharmaceutical Partnerships: 2 strategic alliances
  • Total Collaborative Research Budget: $1.8 million

Sustainable and Responsible Growth

Financial Metric 2024 Performance
Annual Revenue $9.7 million
Net Research Assets $22.3 million
Cash Reserve $15.6 million

DCF model

Hoth Therapeutics, Inc. (HOTH) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.